In his latest opinion piece for the Australian Financial Review, Sam Lovick places some of the blame for COVID-19 vaccine hesitancy in Australia on the communication and vaccine roleout choices that the Commonwealth government has made. These choices make it much less likely that Australia will achieve the required level of vaccination to fully protect […]
In the Australian Financial Review, 13th April 2021, Sam Lovick asks whether possible delays in COVID-19 vaccination resulting from restricted use of the AstraZeneca Oxford vaccine to adults over 50 are more costly than the adverse events that might be avoided. In any pandemic, time to achieve herd immunity is critical in reducing infections, reducimg […]
Genetic Technologies is developing a Polygenic Risk Score (PRS) test for COVID-19 which may enable an assessment of risk of an individual developing a serious disease should they contract the virus. The test is intended to predict ‘disease severity’ using a combination of genetic and clinical information (here). Modelling done by Sam Lovick Consulting using […]
Published in the Australian Financial Review, Dr Brian McNamee AO (writing in his personal capacity) and Sam Lovick question whether Premier Andrews’ roadmap to recovery is the right path. We conclude that Daniel Andrews should move to reduce lock down measures in regional Victoria immediately and should move to do so more quickly in Melbourne. The […]
In a recent article published in the Financial Review, Sam Lovick reiterates that suppression is the best way to balance the health and economic costs of the COVID-19 pandemic. But fearful governments find themselves choosing an elimination strategy anyway.
In a recent article published in the Financial Review, Sam Lovick reviews whether there will be a second wave in Australia. He concludes not as Australia will strive to keep infections low by keeping its borders low. He sets out his concern that this will be much more costly than recent analysis by the OECD […]
In a recent article published in the Financial Review, Sam Lovick reviews whether the costs and benefits of Australia’s current approach to the COVID-19 pandemic stack up. This longer paper provides more information on the disease modelling that we used to understand what the best mode of intervention in the pandemic might be.
In a recent article published in the Financial Review, Sam Lovick reviews whether the costs and benefits of Australia’s current approach to the COVID-19 pandemic stack up. Based on our modelling, which links dynamic disease modelling and broader economic modelling, we conclude that there are alternative modes of intervention that would have a much lower […]
In a recent article published in the Financial Review, Sam Lovick estimates how much Australia is likely to spend for each life saves under the current COVID-19 interventions. He arrives at the somewhat alarming figure of $6m, much more that we are typically willing to spend to prevent an avoidable deaths.